Hypercholesterolaemia: Treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate.
Primary prevention: Reduction of cardiovascular mortality and morbidity in patients with moderate or severe hypercholesterolaemia and at high risk of a first cardiovascular event, as an adjunct to diet (see PHARMACOLOGY: Pharmacodynamics under Actions).
Secondary prevention: Reduction of cardiovascular mortality and morbidity (myocardial infarction, revascularization, ischemic stroke & TIA) in patients with a history of myocardial infarction or unstable angina pectoris and with either normal or increased cholesterol levels, as an adjunct to correction of other risk factors (see PHARMACOLOGY: Pharmacodynamics under Actions).
Post transplantation: Reduction of post transplantation hyperlipidaemia in patients receiving immunosuppressive therapy following solid organ transplantation (see Dosage & Administration, Interactions and PHARMACOLOGY: Pharmacodynamics under Actions).